Allogeneic umbilical cord mesenchymal stem cells

BIOLOGICAL5 trials

Sponsors

Sclnow Biotechnology Co., Ltd., Ever Supreme Bio Technology Co., Ltd.

Conditions

Acute Myocardial InfarctionCOVID-19 InfectionMultiple SclerosisMyelodysplastic SyndromesST Elevation Myocardial Infarction

Phase 1

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

SuspendedNCT03184935

Sclnow Biotechnology Co., Ltd.Myelodysplastic Syndromes

Start: 2026-12-31End: 2027-12-31Target: 40Updated: 2026-04-23

Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction

CompletedNCT04056819

Ever Supreme Bio Technology Co., Ltd.Acute Myocardial Infarction

Start: 2019-05-27End: 2021-12-17Updated: 2024-09-19

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19

Active, not recruitingNCT05501418

Ever Supreme Bio Technology Co., Ltd.COVID-19 Infection

Start: 2020-08-05End: 2025-12-31Target: 75Updated: 2024-08-28

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

RecruitingNCT05532943

Ever Supreme Bio Technology Co., Ltd.Multiple Sclerosis

Start: 2023-09-08End: 2028-10-31Target: 41Updated: 2025-08-07

Phase 2

Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients

RecruitingNCT06147986

Ever Supreme Bio Technology Co., Ltd.ST Elevation Myocardial Infarction

Start: 2023-09-24End: 2027-06-24Target: 41Updated: 2024-09-19